GlassScriptPhysician profile
Bernard Allan Rosenberg
NPI 1568519601
$64,434.68
in general payments reported to CMS, 2019-2025
43 companies · $3,476 in 2025
The $3,476 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $10K · 2021: $21K · 2022: $4,668 · 2023: $2,881 · 2024: $2,840 · 2025: $3,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,103 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,103.44 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $27,345.92 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $15,150.71 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $5,075.63 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,765.81 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,600.11 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,583.04 | 2019-2025 | Abilify Maintena, Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $1,551.57 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $1,046.91 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,000.95 | 2019-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $818.23 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $672.56 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $621.22 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Almatica Pharma LLC | $588.83 | 2021-2025 | Loreev Xr |
| Allergan, INC. | $524.48 | 2019-2020 | |
| Bausch Health US, LLC | $505.86 | 2019-2025 | Aplenzin, Wellbutrin |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $496.66 | 2019-2025 | |
| Axsome Therapeutics, INC. | $482.02 | 2022-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $470.33 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Validus Pharmaceuticals LLC | $443.04 | 2019-2021 | |
| Corium, LLC | $406.63 | 2021-2025 | Azstarys |
| Tris Pharma INC | $351.18 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Noven Therapeutics, LLC | $233.68 | 2022-2025 | Xelstrym, Secuado |
| Avanir Pharmaceuticals, INC. | $217.17 | 2019-2022 | |
| Eisai INC. | $208.94 | 2020-2021 | |
| Indivior INC. | $180.23 | 2020-2022 | |
| Harmony Biosciences LLC | $160.76 | 2020-2022 | |
| Collegium Pharmaceutical, INC. | $137.82 | 2025 | Jornay Pm |
| Avadel Cns Pharmaceuticals, LLC | $129.87 | 2023-2025 | Lumryz |
| E.R. Squibb & Sons, L.L.C. | $104.54 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $78.05 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $77.28 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $62.66 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $58.45 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $53.08 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $51.13 | 2024 | Nuplazid |
| Shire North American Group INC | $39.29 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $29.08 | 2019 | |
| Currax Pharmaceuticals LLC | $28.19 | 2019-2020 | |
| Neuronetics, INC. | $25.48 | 2019 | |
| Endo Pharmaceuticals INC. | $24.41 | 2019 | |
| Alfasigma USA, INC. | $14.76 | 2021 | |
| Brainsway USA INC | $11.74 | 2019 | |
| Aytu Biopharma, INC. | $6.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernard Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.